BACKGROUND: Stimuli from the terminal phase of smoke or drug intake are paired with drug effect but have surprisingly low cue reactivity. Smoking terminal stimuli were compared to cues under conditions of different perceived smoke intake to probe whether (1) terminal stimuli are only weak cues, (2) any effect is an artifact of rigid test conditions, and (3) terminal stimuli have a unique function during the intake ritual. MATERIALS AND METHODS: Nonabstinent, healthy smokers were tested in three experiments with one-session, within-subject cue reactivity tests. Smoking terminal stimuli and cues were compared using pictures depicting events after completion (END) and before start of smoke inhalation (BEGIN). Test pictures were presented alone and in combination with no-go symbols (from no-smoking signs) or with extra cues to decrease and to increase perceived smoke availability, respectively. Measured were subjective effects and affect modulation of the startle reflex. RESULTS: END stimuli relative to BEGIN stimuli evoked less subjective craving and pleasure but more arousal. A no-go stimulus, which reduced reports of intention to smoke, reduced the reactivity to BEGIN but only marginally affected responses to END stimuli. This was confirmed with different sets of test pictures and using tests with the startle response. An extra cue did not affect reactivity to a BEGIN stimulus but increased craving and pleasure to the END stimulus, although not to the level of BEGIN stimuli alone. CONCLUSIONS: This first systematic study of terminal stimuli found their effects to be robust and have test generality. They are probably not weak cues but evoke reactivity, which may oppose reactivity of cues. They may signal poor availability of drug. Methodological, clinical, and theoretical implications were noted.
BACKGROUND: Stimuli from the terminal phase of smoke or drug intake are paired with drug effect but have surprisingly low cue reactivity. Smoking terminal stimuli were compared to cues under conditions of different perceived smoke intake to probe whether (1) terminal stimuli are only weak cues, (2) any effect is an artifact of rigid test conditions, and (3) terminal stimuli have a unique function during the intake ritual. MATERIALS AND METHODS: Nonabstinent, healthy smokers were tested in three experiments with one-session, within-subject cue reactivity tests. Smoking terminal stimuli and cues were compared using pictures depicting events after completion (END) and before start of smoke inhalation (BEGIN). Test pictures were presented alone and in combination with no-go symbols (from no-smoking signs) or with extra cues to decrease and to increase perceived smoke availability, respectively. Measured were subjective effects and affect modulation of the startle reflex. RESULTS: END stimuli relative to BEGIN stimuli evoked less subjective craving and pleasure but more arousal. A no-go stimulus, which reduced reports of intention to smoke, reduced the reactivity to BEGIN but only marginally affected responses to END stimuli. This was confirmed with different sets of test pictures and using tests with the startle response. An extra cue did not affect reactivity to a BEGIN stimulus but increased craving and pleasure to the END stimulus, although not to the level of BEGIN stimuli alone. CONCLUSIONS: This first systematic study of terminal stimuli found their effects to be robust and have test generality. They are probably not weak cues but evoke reactivity, which may oppose reactivity of cues. They may signal poor availability of drug. Methodological, clinical, and theoretical implications were noted.
Authors: P J Bushnell; E D Levin; R T Marrocco; M F Sarter; B J Strupp; D M Warburton Journal: Neurotoxicol Teratol Date: 2000 Jul-Aug Impact factor: 3.763
Authors: Ronald N Ehrman; Steven J Robbins; Melissa A Bromwell; Megan E Lankford; John R Monterosso; Charles P O'Brien Journal: Drug Alcohol Depend Date: 2002-07-01 Impact factor: 4.492
Authors: Brian L Carter; Jason D Robinson; Cho Y Lam; David W Wetter; Jack Y Tsan; Susan X Day; Paul M Cinciripini Journal: Nicotine Tob Res Date: 2006-06 Impact factor: 4.244
Authors: Bastian Stippekohl; Bertram Walter; Markus H Winkler; Ronald F Mucha; Paul Pauli; Dieter Vaitl; Rudolf Stark Journal: Psychopharmacology (Berl) Date: 2012-04-03 Impact factor: 4.530
Authors: Bastian Stippekohl; Markus Winkler; Ronald F Mucha; Paul Pauli; Bertram Walter; Dieter Vaitl; Rudolf Stark Journal: Neuropsychopharmacology Date: 2010-01-20 Impact factor: 7.853
Authors: Miguel Angel Muñoz; Sofía Idrissi; María Blasa Sánchez-Barrera; Ma Carmen Fernández; Jaime Vila Journal: Psychopharmacology (Berl) Date: 2011-05-19 Impact factor: 4.530
Authors: Markus H Winkler; Peter Weyers; Ronald F Mucha; Bastian Stippekohl; Rudolf Stark; Paul Pauli Journal: Psychopharmacology (Berl) Date: 2010-10-15 Impact factor: 4.530
Authors: Charlotte E Wittekind; Keisuke Takano; Philipp Sckopke; Markus H Winkler; Gabriela G Werner; Thomas Ehring; Tobias Rüther Journal: Trials Date: 2022-03-21 Impact factor: 2.279
Authors: Bastian Stippekohl; Markus H Winkler; Bertram Walter; Sabine Kagerer; Ronald F Mucha; Paul Pauli; Dieter Vaitl; Rudolf Stark Journal: PLoS One Date: 2012-11-14 Impact factor: 3.240